Education
About Us
Working with TipRanks
Follow Us
Forte Biosciences Inc. (FBRX)
NASDAQ:FBRX
Total Valuation
Forte Biosciences has a market cap or net worth of $135.64M. The enterprise value is $45.71M.
Market Cap$135.64M
Enterprise Value$45.71M
Share Statistics
Forte Biosciences has 12,432,854 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding12,432,854
Owned by Insiders2.90%
Owned by Institutions48.00%
Financial Efficiency
Forte Biosciences’s return on equity (ROE) is -0.68 and return on invested capital (ROIC) is -69.74%.
Return on Equity (ROE)-0.68
Return on Assets (ROA)-0.58
Return on Invested Capital (ROIC)-69.74%
Return on Capital Employed (ROCE)-0.70
Revenue Per Employee0.00
Profits Per Employee-2.53M
Employee Count14
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Forte Biosciences is ―. Forte Biosciences’s PEG ratio is 0.04.
PE Ratio―
PS Ratio0.00
PB Ratio1.26
Price to Fair Value1.26
Price to FCF-2.15
Price to Operating Cash Flow-8.01
PEG Ratio0.04
Income Statement
In the last 12 months, Forte Biosciences had revenue of 0.00 and earned -35.48M in profits. Earnings per share was -12.17.
Revenue0.00
Gross Profit-39.00K
Operating Income-36.60M
Pretax Income-35.48M
Net Income-35.48M
EBITDA-35.44M
Earnings Per Share (EPS)-12.17
Cash Flow
In the last 12 months, operating cash flow was -44.42M and capital expenditures -147.00K, giving a free cash flow of -44.57M billion.
Operating Cash Flow-44.42M
Free Cash Flow-44.57M
Free Cash Flow per Share-3.59
Dividends & Yields
Forte Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.64
52-Week Price Change12.71%
50-Day Moving Average15.50
200-Day Moving Average11.14
Relative Strength Index (RSI)63.28
Average Volume (3m)97.46K
Important Dates
Forte Biosciences upcoming earnings date is Mar 24, 2026, After Close (Confirmed).
Last Earnings DateNov 14, 2025
Next Earnings DateMar 24, 2026
Ex-Dividend Date―
Financial Position
Forte Biosciences as a current ratio of 6.76, with Debt / Equity ratio of 0.00%
Current Ratio6.76
Quick Ratio6.76
Debt to Market Cap0.00
Net Debt to EBITDA0.63
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Forte Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Forte Biosciences EV to EBITDA ratio is -1.24, with an EV/FCF ratio of -1.43.
EV to Sales0.00
EV to EBITDA-1.24
EV to Free Cash Flow-1.43
EV to Operating Cash Flow-1.43
Balance Sheet
Forte Biosciences has $93.41M in cash and marketable securities with $0.00 in debt, giving a net cash position of $93.41M billion.
Cash & Marketable Securities$93.41M
Total Debt$0.00
Net Cash$93.41M
Net Cash Per Share$7.51
Tangible Book Value Per Share$18.00
Margins
Gross margin is -23.68%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-23.68%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Forte Biosciences is $65.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$65.00
Price Target Upside204.16% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast77.08%